ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

BRL Medicine, AstraZeneca and Fosun Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

BRL Medicine×AstraZeneca×Fosun Pharma×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

BRL MedicineAstraZenecaFosun Pharma
studies on the registry244,197202
open to participants now1429886
phase 3 studies under way020023
reach primary completion within a year316839
programswith a study of their own in two years2119+5 named only49+18 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBRL MedicineAstraZenecaFosun Pharma
Phase 1

BRL Medicine: 2 of its 2 programs at phase 1

  1. BRL-301no phase
  2. Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injectionno phase
100%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Fosun Pharma: 27 of its 49 programs at phase 1

  1. HLX319phase 1
  2. Anti-PD-1/IL-2 Fusion Protein TEV-56278phase 1
  3. Cetuximabphase 1
  4. FXS0260phase 1
  5. FXS0683phase 1

and 22 more — sign in to see them all

55%
Phase 200%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Fosun Pharma: 9 of its 49 programs at phase 2

  1. BRAF V600E Inhibitor HLX208phase 2
  2. Bcl-2 Inhibitor LOXO-338phase 2
  3. FKC289phase 2
  4. FXR0906phase 2
  5. XH-S003 Capsulephase 2

and 4 more — sign in to see them all

18%
Phase 300%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Fosun Pharma: 13 of its 49 programs at phase 3

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. luvometinibphase 3
  5. dulpatatugphase 3

and 8 more — sign in to see them all

27%
Approved, new studies00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
BRL Medicine2 readouts · 0 phase 3····

BRL Medicine, Mar ’27: 1 program whose next study reaches primary completion

  1. Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injectionno phase · Mar 15 · NCT07248176
····

BRL Medicine, Aug ’27: 1 program whose next study reaches primary completion

  1. BRL-301no phase · Aug 15 · NCT07248163
··
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Fosun Pharma21 readouts · 3 phase 3

Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3 · Nov 22 · NCT06839066
  2. FKC876early phase 1 · Nov 30 · NCT07606937

Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion

  1. HLX13phase 3 · Dec 0 · NCT07176650
  2. Bcl-2 Inhibitor LOXO-338phase 2 · Dec 1 · NCT06858618

Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion

  1. HLX29phase 1 · Jan 31 · NCT07776132

Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion

  1. FXS5626phase 3 · Feb 28 · NCT07552012

Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. HLX48phase 1 · Mar 0 · NCT07473726
  2. HLX37phase 3 · Mar 30 · NCT07274813

Fosun Pharma, Apr ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. HLX17phase 3 · Apr 9 · NCT06847334
  2. HLX319phase 1 · Apr 23 · NCT07601620
  3. FXS887phase 1 · Apr 28 · NCT07345637
  4. FXS6837phase 3 · Apr 29 · NCT07949799
  5. luvometinibphase 3 · Apr 30 · NCT07004075

Fosun Pharma, May ’27: 1 program whose next study reaches primary completion

  1. HLX15phase 3 · May 25 · NCT07477587

Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. dulpatatugphase 3 · Jun 1 · NCT06532006
  2. HLX3902phase 1 · Jun 29 · NCT07533708
  3. Cetuximabphase 1 · Jun 30 · NCT07543471

Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion

  1. pimurutamabphase 3 · Jul 28 · NCT07358585

Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. HLX18phase 1 · Aug 12 · NCT07518043

Fosun Pharma, Sep ’27: 2 programs whose next study reaches primary completion

  1. HLX109phase 1 · Sep 20 · NCT07935941
  2. FXR0906phase 2 · Sep 24 · NCT07766759
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

BRL Medicine

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Fosun Pharma

New programs 5

  • HLX49phase 1 · first study · Nov 12
  • HLX105phase 1 · first study · Nov 4
  • FXS0260phase 1 · first study · Oct 25
  • HLX109phase 1 · first study · Oct 18
  • FXS4640phase 1 · first study · Sep 23

Reached a new phase 3

  • FXR0906phase 2 · Oct 13
  • HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
  • FXS5626phase 3 · Sep 17 · Uveitis

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 29 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBRL MedicineAstraZenecaFosun Pharma
Multiple Myelomaall three · compare here

Fosun Pharma in Multiple Myeloma: 2 programs

  1. HLX15phase 3
  2. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Multiple Myeloma in search

Lymphoma, B-Cellall three · compare here

BRL Medicine in Lymphoma, B-Cell: 1 program

  1. BRL-301no phase

Their studies: BRL Medicine’s studies of Lymphoma, B-Cell in search

Fosun Pharma in Lymphoma, B-Cell: 2 programs

  1. FXS0683phase 1
  2. XS-04phase 1

Their studies: Fosun Pharma’s studies of Lymphoma, B-Cell in search

Carcinoma, Non-Small-Cell Lung2 of 3 · compare here–

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Fosun Pharma in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. HLX17phase 3
  5. HLX37phase 3

and 6 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasms2 of 3 · compare here–

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Fosun Pharma in Breast Neoplasms: 6 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. dulpatatugphase 3
  3. HLX87phase 3
  4. hx22phase 3
  5. HLX319phase 1

and 1 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Breast Neoplasms in search

Neoplasms2 of 3 · compare here–

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Fosun Pharma in Neoplasms: 5 programs

  1. anlotinibphase 2
  2. Folfox protocolphase 2
  3. Cetuximabphase 1
  4. HLX05phase 1
  5. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Neoplasms in search

Stomach Neoplasms2 of 3 · compare here–

Fosun Pharma in Stomach Neoplasms: 3 programs

  1. serplulimabphase 3
  2. dulpatatugphase 3
  3. Folfox protocolphase 2

Their studies: Fosun Pharma’s studies of Stomach Neoplasms in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Fosun Pharma in Pulmonary Disease, Chronic Obstructive: 1 program

  1. fxs7553 doseno phase

Their studies: Fosun Pharma’s studies of Pulmonary Disease, Chronic Obstructive in search

Renal Insufficiency2 of 3 · compare here–

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Fosun Pharma in Renal Insufficiency: 1 program

  1. nacubactamno phase

Their studies: Fosun Pharma’s studies of Renal Insufficiency in search

Carcinoma, Hepatocellular2 of 3 · compare here–

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Fosun Pharma in Carcinoma, Hepatocellular: 1 program

  1. HLX13phase 3

Their studies: Fosun Pharma’s studies of Carcinoma, Hepatocellular in search

Colorectal Neoplasms2 of 3 · compare here–

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Fosun Pharma in Colorectal Neoplasms: 5 programs

  1. serplulimabphase 3
  2. BRAF V600E Inhibitor HLX208phase 2
  3. Folfox protocolphase 2
  4. XS-03phase 2
  5. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Colorectal Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Fosun Pharma in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. Bcl-2 Inhibitor LOXO-338phase 2

Their studies: Fosun Pharma’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Endometrial Neoplasms2 of 3 · compare here–

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Fosun Pharma in Endometrial Neoplasms: 1 program

  1. anlotinibphase 2

Their studies: Fosun Pharma’s studies of Endometrial Neoplasms in search

Show all 29

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: BRL Medicine 0 of 2 · AstraZeneca 68 of 119 · Fosun Pharma 25 of 49 programs (36 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Fosun Pharma: 18).